Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

NCT03459170 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancy

Interventions

BIOLOGICAL: BPX-501 T cells
DRUG: rimiducid

Sponsor

Bellicum Pharmaceuticals